Novavax Inc (NVAX) Stock Analysis

Verdict: WATCH (do not buy)

Momentum driven by NIH cancer vaccine hype masks negative book value (-$127.8M) and 12-month cash burn runway risks.

Investment score: 46/100

Analysis as of 2026-10-15

Is Novavax Inc stock worth reviewing? The TradeMates thesis

The model views Novavax as a speculative momentum vehicle where recent news tailwinds collide with fundamental balance sheet distress and an exhausted equity base.

7-factor investment score

Valuation: 35/100 (weight 20%)
Financial Health: 20/100 (weight 15%)
Technical Momentum: 75/100 (weight 15%)
Earnings Quality: 65/100 (weight 15%)
Insider Sentiment: 50/100 (weight 10%)
Analyst Consensus: 55/100 (weight 10%)
Risk-Adjusted Return: 30/100 (weight 15%)

Novavax Inc opportunities and risks

What speaks for NVAX

Matrix-M adjuvant platform and commercial partnerships provide licensing upside.

What speaks against NVAX

Impending cash exhaustion runway within 12 months.

Peers and competitors

RXRX
VRDN
IRON
VCEL
VERA
IMNM
BCRX
ZBIO

Trailing-twelve-month ratios
Ticker	P/E	P/S	EV/EBITDA	Gross margin	Net margin	FCF yield
NVAX	n/a	5.1x	n/a	77.9%	-59.9%	-2.1%
RXRX	n/a	40.6x	n/a	-46.7%	-945.9%	-15.9%
VRDN	n/a	31.2x	n/a	99.6%	-544.1%	-15.1%
IRON	n/a	0.0x	n/a	0.0%	0.0%	-9.1%
VCEL	85.5x	6.9x	53.3x	74.6%	7.9%	2.4%
VERA	n/a	0.0x	n/a	0.0%	0.0%	-16.5%
Peer median	n/a	6.9x	n/a	0.0%	0.0%	-15.1%

Frequently asked questions about Novavax Inc (NVAX)

Is NVAX stock a good investment?

The TradeMates model rates Novavax Inc as WATCH (do not buy) with an investment score of 46/100. The model views Novavax as a speculative momentum vehicle where recent news tailwinds collide with fundamental balance sheet distress and an exhausted equity base. This is algorithmic model output, not personal investment advice.

Is NVAX stock a buy?

The TradeMates model verdict for NVAX is WATCH (do not buy) with an investment score of 46/100. Treat this as a model signal to review, not a personal buy recommendation.